Rigel Pharmaceuticals (RIGL +0.4%) says it's made clinical advancement in three programs...


Rigel Pharmaceuticals (RIGL +0.4%) says it's made clinical advancement in three programs currently in development. The first program is R348, a topical ophthalmic formulation of a JAK/SYK inhibitor being developed to treat dry eye disease. The company notes that the drug was well tolerated in Phase 1 trials, and it plans to initiate Phase 2 trials soon. The other two are oncology programs being conducted by corporate partners, including an AXL kinase inhibitor under development by BerGenBio AS and a ligase inhibitor by Daiichi Sankyo (DSNKY.PK).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs